drugset / Trial / NCT04352465

Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients

NCT04352465

Non-randomizedSequentialOpen-labelTreatment

Summary

The aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.

Timeline

Start
2020-05-01
Primary completion
2020-06-30
Completion
2020-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 20 mg Intravenous
Subject Methotrexate Small molecule 30 mg Intravenous
Subject Methotrexate Small molecule 40 mg Intravenous

Indications